NASDAQ:RXRX Recursion Pharmaceuticals (RXRX) Stock Price, News & Analysis $5.70 +0.29 (+5.36%) Closing price 04:00 PM EasternExtended Trading$5.70 0.00 (-0.04%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Recursion Pharmaceuticals Stock (NASDAQ:RXRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RXRX alerts:Sign Up Key Stats Today's Range$5.52▼$5.8250-Day Range$4.57▼$6.5452-Week Range$3.79▼$12.36Volume23.38 million shsAverage Volume25.08 million shsMarket Capitalization$2.32 billionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingHold Company Overview Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Read More Recursion Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreRXRX MarketRank™: Recursion Pharmaceuticals scored higher than 30% of companies evaluated by MarketBeat, and ranked 642nd out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingRecursion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageRecursion Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Recursion Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Recursion Pharmaceuticals are expected to grow in the coming year, from ($1.57) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Recursion Pharmaceuticals is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Recursion Pharmaceuticals is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRecursion Pharmaceuticals has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted34.95% of the float of Recursion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRecursion Pharmaceuticals has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Recursion Pharmaceuticals has recently decreased by 1.60%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRecursion Pharmaceuticals does not currently pay a dividend.Dividend GrowthRecursion Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted34.95% of the float of Recursion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRecursion Pharmaceuticals has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Recursion Pharmaceuticals has recently decreased by 1.60%, indicating that investor sentiment is improving. News and Social Media3.1 / 5News Sentiment0.55 News SentimentRecursion Pharmaceuticals has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Recursion Pharmaceuticals this week, compared to 10 articles on an average week.Search Interest112 people have searched for RXRX on MarketBeat in the last 30 days. This is an increase of 138% compared to the previous 30 days.MarketBeat Follows37 people have added Recursion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 32% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Recursion Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.43% of the stock of Recursion Pharmaceuticals is held by insiders.Percentage Held by Institutions89.06% of the stock of Recursion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Recursion Pharmaceuticals' insider trading history. Receive RXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RXRX Stock News HeadlinesRecursion Pharmaceuticals: Two Clinical Readouts In H2'255 hours ago | seekingalpha.comRecursion Pharmaceuticals’ Earnings Call Highlights Progress and ChallengesAugust 11 at 9:41 AM | theglobeandmail.comOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.August 13 at 2:00 AM | InvestorPlace (Ad)3 Brilliant Growth Stocks to Buy Now and Hold for the Long TermAugust 10 at 5:20 AM | fool.comHead to Head Comparison: Recursion Pharmaceuticals (NASDAQ:RXRX) & Addex Therapeutics (NASDAQ:ADXN)August 10 at 2:10 AM | americanbankingnews.comLeerink Partnrs Has Positive Outlook of RXRX Q3 EarningsAugust 10 at 2:31 AM | americanbankingnews.comIs Recursion Pharmaceuticals (RXRX) Nvidia's Key AI Biotech Stake a Buy Amid Innovation Surge?August 8, 2025 | 247wallst.comBroker Revenue Forecasts For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging HigherAugust 6, 2025 | finance.yahoo.comSee More Headlines RXRX Stock Analysis - Frequently Asked Questions How have RXRX shares performed this year? Recursion Pharmaceuticals' stock was trading at $6.76 at the beginning of the year. Since then, RXRX shares have decreased by 15.6% and is now trading at $5.7050. How were Recursion Pharmaceuticals' earnings last quarter? Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced its quarterly earnings data on Tuesday, August, 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by $0.06. The business's revenue for the quarter was up 33.3% on a year-over-year basis. Read the conference call transcript. When did Recursion Pharmaceuticals IPO? Recursion Pharmaceuticals (RXRX) raised $306 million in an initial public offering on Friday, April 16th 2021. The company issued 18,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets served as the underwriters for the IPO. Who are Recursion Pharmaceuticals' major shareholders? Top institutional investors of Recursion Pharmaceuticals include ARK Investment Management LLC (8.12%), Sumitomo Mitsui Trust Group Inc. (2.01%), Geode Capital Management LLC (1.91%) and Norges Bank (0.78%). Insiders that own company stock include Mubadala Investment Co Pjsc, Blake Borgeson, Michael Secora, Christopher Gibson, Tina Marriott, Dean Y Li, Tina Marriott Larson, Shafique Virani, Terry-Ann Burrell and Zavain Dar. View institutional ownership trends. How do I buy shares of Recursion Pharmaceuticals? Shares of RXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Recursion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Recursion Pharmaceuticals investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/05/2025Today8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RXRX CIK1601830 Webwww.recursion.com Phone385-269-0203Fax801-821-2872Employees400Year FoundedN/APrice Target and Rating Average Price Target for Recursion Pharmaceuticals$7.00 High Price Target$10.00 Low Price Target$5.00 Potential Upside/Downside+24.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$463.66 million Net Margins-1,004.91% Pretax Margin-1,004.88% Return on Equity-76.09% Return on Assets-54.29% Debt Debt-to-Equity Ratio0.02 Current Ratio3.58 Quick Ratio3.58 Sales & Book Value Annual Sales$58.84 million Price / Sales38.79 Cash FlowN/A Price / Cash FlowN/A Book Value$2.26 per share Price / Book2.48Miscellaneous Outstanding Shares406,490,000Free Float372,227,000Market Cap$2.28 billion OptionableOptionable Beta0.93 10 Stocks Set to Soar in Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:RXRX) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.